trending Market Intelligence /marketintelligence/en/news-insights/trending/eOxwheKvKzL-7dsUkLAIQg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Pluristem to advance blood transplant study

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Pluristem to advance blood transplant study

Pluristem Therapeutics Inc. is collaborating with the New York Blood Center to advance studies on its PLX-R18 therapy for umbilical cord blood transplantation.

The study will be funded by a conditional award of $900,000 from the Israel-U.S. Binational Industrial Research and Development Foundation with Pluristem providing the PLX-R18 cells and the NYBC conducting and supporting the studies.